FDA grants orphan drug designation to MDS investigational therapy ofirnoflast
The US Food and Drug Administration (FDA) has granted orphan drug designation to ofirnoflast (HT-6184), an investigational therapy for myelodysplastic symptoms (MDS).
Myelodysplastic Syndromes
News
Leukemia
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
News
US launch of tyrosine kinase inhibitor in Ph+ CML, ALL
Cycle Pharmaceuticals launched dasatinib tablets (PHYRAGO). It's a tyrosine kinase inhibitor bioequivalent to Sprycel. The drug treats adults with newly diagnosed or resistant/intolerant
Ambassador Program
Myelodysplastic Syndromes
Society Updates
SOHO MENA returns to in-person meeting for region’s 3rd meeting
Now in its third year, the meeting featured a comprehensive program covering all blood cancers, bringing together world-class clinicians including Drs. Hagop Kantarjian,
SOHO 2025
Educational Resources
Leukemia
Meetings / Conferences
Myelodysplastic Syndromes
News
Improving Outcomes in CHIP/CCUS with Dr. Borate
This Meet the Professor session was delivered by Uma Borate, MD, MS, an associate professor at the Ohio State University Comprehensive Cancer Center,
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndromes
News
FDA accepts BLA for Orca-T in hematological malignancies
The US Food and Drug Administration (FDA) accepted for priority review the Biologics License Application (BLA) seeking approval for Orca-T (Orca-T), an investigational
Leukemia News
SOHO 2025
Educational Resources
Acute Myeloid Leukemia
Meetings / Conferences
News
Future Role of CPX-351 and CPX-351-Based Combinations
In this Meet the Professor session in acute myeloid leukemia, Jeffrey Lancet, MD, chair of the Department of Malignant Hematology at the Moffitt
Lymphoma
Mantle Cell Lymphoma
News
FDA grants breakthrough therapy designation to sonrotoclax in relapsed or refractory MCL
The United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for sonrotoclax, a next-generation investigational BCL2 inhibitor, for adult patients with
Leukemia News
SOHO 2025
Drs. Kantarjian and Mauro discuss ELVN-001 in CML
In this video interview, Hagop Kantarjian, MD, speaks with Michael Mauro, MD, leader of the CML program at Memorial Sloan Kettering Cancer Center,
Leukemia
Acute Myeloid Leukemia
SOHO Insider Podcast
Dr. Eytan Stein joins Dr. Saad Usmani on SOHO Insider podcast
Saad Usmani, MD, chief of the myeloma service and Eytan Stein, MD, chief of the leukemia service, both from Memorial Sloan Kettering Cancer
Lymphoma News
SOHO 2025
News
BTK ‘degrader’ bexdeg shines in Waldenström macroglobulinemia
Attendees of SOHO 2025 will get a closer look at positive early safety and efficacy data for the novel Bruton’s tyrosine kinase (BTK)-targeted